Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07412730
PHASE2

Glucose Tolerance Study

Sponsor: RDC Clinical Pty Ltd

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to assess whether TRPTI (oleoylethanolamide) can improve glucose tolerance in healthy adults aged 18 years and above with BMI 18.5-29.9 kg/m². The main questions it aims to answer are: * Does TRPTI improve glucose tolerance as measured by glucose area under the curve (AUC) from 0-120 minutes following a glucose load? * Does TRPTI reduce peak glucose response and alter the time to peak glucose concentration? * Are there dose-dependent effects between 150 mg and 300 mg doses of TRPTI? Researchers will compare TRPTI 150 mg, TRPTI 300 mg, and placebo in a crossover design to see if TRPTI improves glucose metabolism and insulin sensitivity compared to placebo. Participants will complete 3 clinic visits (each lasting approximately 4 hours) with a minimum 6-day washout period between visits.

Official title: A Randomised, Double-blind, Placebo-controlled Crossover Study to Assess the Effect of TRPTI (Oleoylethanolamide) on Glucose Tolerance in Healthy Adults

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-03

Completion Date

2027-03

Last Updated

2026-02-17

Healthy Volunteers

Yes

Interventions

DIETARY_SUPPLEMENT

TRPTI 150mg

Single dose of 150mg TRPTI will be orally administered.

DIETARY_SUPPLEMENT

TRPTI 300mg

Single dose of 300mg TRPTI will be orally administered.

OTHER

Placebo

Single dose of placebo will be orally administered.

Locations (1)

RDC Clinical

Brisbane, Queensland, Australia